Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Balsalazide Disodium Tablets in Ulcerative Colitis
NCT00486031Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Oct 2006
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of balsalazide in ulcerative colitis (UC), sponsored by Valeant Pharmaceuticals. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 24 months. Started Oct 2006; status: completed.
02
Drugs
balsalazide
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00486031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00486031.